



Novartis India Limited
Registered Office:
Sandoz House
Shivsagar Estate
Dr. Annie Besant Road
Worli, Mumbai 400 018
India
Tel +91 22 2495 8400
Fax +91 22 2495 0221
CIN No. L24200MH1947PLC006104
Website: www.novartis.in
Email : india.investors@novartis.com

The Secretary
Bombay Stock Exchange
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

May 8, 2017

Sub: Disclosure under Regulation 30(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

1. Pursuant to Regulation 30 (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we Novartis India Limited (“NIL”) would like to inform that Novartis AG (“NVS AG”), vide its letter dated 8th May, 2017, has informed the Board of Directors of Novartis India Limited, that it has entered into an asset sale agreement with Torrent Pharmaceuticals Ltd (‘Torrent’), pursuant to which NVS AG has agreed to sell to Torrent Novartis brand (Regestrone) including the intellectual property rights residing in the related product dossier (“Brand”) (“Transaction”).
2. We were also informed by NVS AG that the said Transaction was approved by the Competition Commission of India on 20th April, 2017.
3. Accordingly it may be noted that, effective 8th May, 2017, Novartis India Limited will cease to have the ability to market or otherwise use the Brand in any manner whatsoever.

This is for your information and record.

For Novartis India Limited



Trivikram Guda
Company Secretary &
Compliance Officer